Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of ABBV-184 in previously treated AML and NSCLC
jRCT2080225199Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of ABBV-184 in acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability of ABBV-184, Pharmacokinetics of ABBV-184 and 1 more. Started May 2020; status: terminated.
02
Drugs
ABBV-184
03
Conditions
acute myeloid leukemia (AML)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225199.